Tremelimumab: beside a new treatment under test
23 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaNot yet recruitingNCT07511504Phase 2Report a problem
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRecruitingNCT07175441Phase 2Report a problem
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)RecruitingNCT06698250Phase 2Report a problem
- Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)RecruitingNCT06564623Phase 1Report a problem
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT03606967Phase 2Report a problem
- GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsCompletedNCT03693612Phase 1/2Results postedReport a problem
- A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal CancerCompletedNCT03206073Phase 1/2Results postedReport a problem
- Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCCompletedNCT03164772Phase 1/2Results postedReport a problem
- A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid TumorsCompletedNCT02718911Phase 1Results postedReport a problem
- A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)TerminatedNCT02616185Phase 1Results postedReport a problem
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckCompletedNCT02499328Phase 1/2Results postedReport a problem
- A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesTerminatedNCT02205333Phase 1/2Results postedReport a problem
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and TremelimumabActive, not recruitingNCT06710223Phase 1Report a problem
- BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular CarcinomaWithdrawnNCT06608940Phase 1/2Report a problem
- Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1Report a problem
- Trial in Patients With Relapsed Ovarian CancerCompletedNCT03267589Phase 2Report a problem
- MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.CompletedNCT03089645Phase 1Report a problem
- SGI-110 Plus Durvalumab/Tremelimumab in SCLCCompletedNCT03085849Phase 1Report a problem
- A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid TumorsCompletedNCT02705482Phase 1Report a problem
- A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1Report a problem
- Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous MelanomaWithdrawnNCT02535078Phase 1/2Report a problem
- Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsCompletedNCT02301130Phase 1Report a problem
- Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV MelanomaCompletedNCT02141542Phase 1Report a problem